Ad-Free Clinical AI for UK Doctors (2026): The Short List

If you want clinical AI that carries no advertising and is available to UK doctors, the practical list in 2026 is short: iatroX for point-of-care questions, The Monday Clinical Brief for keeping up with the literature, and Heidi Evidence if you are not on an NHS email. Praxis Medicine and Umbil are newer UK-focused entrants worth watching. This page explains what each one does, what it costs, and the job it is built for.

"Ad-free" became a category claim in 2026. We think it is worth taking seriously — but only alongside an honest account of what each tool actually does.

What "ad-free" means, and why it matters here

An ad-free clinical tool carries no advertising, and its output is not shaped by who is paying. The summary, the answer, the alert — you get the same one whether or not a sponsor has an interest in it.

Ad-supported tools are not worthless. Many UK doctors use Medscape, Doctors.net.uk and Read by QxMD daily, and they are useful. But a doctor leaning on a tool at the point of care has a reasonable interest in knowing the output was not nudged by a paying advertiser. For clinical content, the absence of that nudge is a feature, not a slogan.

The list below is limited to tools that meet two tests: no advertising, and a credible UK footing.

The short list

The Monday Clinical Brief — keeping up with the literature

Job: tells you what was published last week. A weekly email digest covering every article from the top five journals across 31 specialties, summarised and delivered every Monday. Push, not pull — it surfaces what is new before you have a patient who makes the question urgent. Cost: £20 a year, four-week free trial. UK status: available now. Built for UK clinicians; Claude-summarised; ad-free since launch. Not for: point-of-care lookup. It is reading, not a query tool. (That is us — and we will tell you when another tool is the better fit.)

iatroX — point-of-care clinical questions

Job: answers the clinical question you bring to it, grounded in UK sources — NICE, CKS and SmPC — with calculators and exam Q-banks alongside. Cost: free core tier; Premium around £99 a year adds international Q-banks; specialist diploma banks priced separately. UK status: available. UK-built, MHRA-registered as a Class I device, UKCA-marked. In 2026 it is the pull tool a UK NHS reader can reliably sign up for. Not for: systematic weekly coverage. It responds to queries, not calendars. We have no commercial relationship with iatroX — we list it because it is the option that works.

Heidi Evidence — strong, but check your email domain

Job: citation-backed clinical answers grounded in NICE, BMJ Group, MIMS and HealthPathways. Ad-free, ISO 42001 audited, built on Claude. Cost: free for individuals. UK status: restricted. The Evidence feature does not currently enrol UK NHS email addresses, so NHS clinicians cannot use it. Heidi Scribe — the AI documentation tool — is separately MHRA-cleared and remains available. See our Heidi Evidence vs MCB comparison and the NHS exclusion explainer. Not for: UK NHS accounts, today. The product is good; the door is not open.

Praxis Medicine — new, well-funded, worth watching

Job: clinical AI search grounded in UK-first sources — NICE Guidelines, NICE CKS, NHS Digital and Europe PMC. Cost: not yet public. UK status: newly launched (April 2026), backed by Balderton Capital and Creandum. UK-first source grounding, but individual availability and pricing are still settling. Not for: anyone who needs a fixed answer on cost or access yet. One to track.

Umbil — small, UK-native

Job: a UK clinical workflow assistant drawing strictly on NICE, CKS, SIGN and BNF. Cost: not public. UK status: early-stage, UK-native, source-strict. Credible but small. Not for: anyone needing proven scale. Promising, unproven.

How to choose

Most UK doctors do not need to pick one. The two jobs are different, and the strongest setup covers both:

• A pull tool for questions you bring — iatroX for NHS readers today; Heidi Evidence if your email domain is enrolled.
• A push tool for questions you did not know to ask — a weekly digest, so a guideline change or landmark trial does not pass you by.

One is preventive; the other is acute. Evidence suggests doctors who keep a fixed weekly reading habit produce more consistent CPD portfolios than those who read only reactively — so if you have to invest in one habit, make it the reading.

A note on regulation

Several capable clinical AI tools are excluded from UK use while the regulatory framework settles. The MHRA Medical Devices (Amendment) Regulations consultation closes on 19 June 2026, with further framework expected later in the year. That is the backdrop to why a US tool may be excellent and still unavailable here — and why UK-footed tools matter for now.

This list is current as of June 2026 and is reviewed each scan. If a tool's access or pricing changes, we update the entry.